Systemic inflammatory markers for the detection of infectious complications and safe discharge after cytoreductive surgery and HIPEC

Surg Oncol. 2020 Sep:34:163-167. doi: 10.1016/j.suronc.2020.04.013. Epub 2020 Apr 18.

Abstract

Introduction: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) in patients with ovarian peritoneal carcinomatosis may be associated with a high postoperative morbidity. An early discrimination of postoperative complications is crucial for both improving clinical outcomes and proposing a safe discharge.

Material and methods: In a cohort of 122 patients with advanced ovarian cancer (FIGO III-IV), we analyzed the diagnostic performance of three systemic inflammatory markers (C-reactive protein, white blood cell count and systemic immune-inflammation index) between the 5th to 8th postoperative days to prediction postoperative infectious complications. An optimal cut-off value was established in order to discriminate between the group of patients who developed infectious complications or not during the postoperative period.

Results: The median peritoneal carcinomatosis index (PCI) was 15. The overall infectious morbidity was 25.4% (31 patients out of 122), of which, 32% (10 patients out of 31) had suffered severe postoperative complications (Dindo-Clavien III-IV). The most accurate results for detecting infectious complications were obtained by using C-reactive protein, which presented an excellent diagnostic performance, especially on the 7th and 8th postoperative days (AUC = 0,857 and 0,920; respectively).

Conclusions: These results support that it is safe to discharge patients with C-reactive protein concentrations lower than 88 mg/L and 130 mg/L, on the 7th and 8th postoperative days, respectively.

Keywords: C-reactive protein; Ovarian; Peritoneal carcinomatosis; Postoperative infectious complication.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Biomarkers, Tumor / blood
  • Chemotherapy, Cancer, Regional Perfusion / adverse effects*
  • Combined Modality Therapy
  • Communicable Diseases / blood
  • Communicable Diseases / diagnosis*
  • Communicable Diseases / etiology
  • Cytoreduction Surgical Procedures / adverse effects*
  • Female
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced / adverse effects*
  • Hyperthermic Intraperitoneal Chemotherapy / adverse effects*
  • Inflammation Mediators / blood*
  • Ovarian Neoplasms / pathology
  • Ovarian Neoplasms / therapy*
  • Postoperative Complications / blood
  • Postoperative Complications / diagnosis*
  • Postoperative Complications / etiology
  • Prognosis
  • Prospective Studies
  • Receptors, Immunologic / blood
  • Retrospective Studies

Substances

  • Biomarkers, Tumor
  • CRP protein, human
  • Inflammation Mediators
  • Receptors, Immunologic